低收入国家的霍奇金淋巴瘤:多哥的经验

Essohana Padaro, K. M. C. Womey, Yao Layibo, Kadara R Adandodo, Hèzouwè Magnang, Mensah D I Kueviakoe
{"title":"低收入国家的霍奇金淋巴瘤:多哥的经验","authors":"Essohana Padaro, K. M. C. Womey, Yao Layibo, Kadara R Adandodo, Hèzouwè Magnang, Mensah D I Kueviakoe","doi":"10.14302/issn.2372-6601.jhor-24-4962","DOIUrl":null,"url":null,"abstract":"While highly curable in developed countries, Hodgkin's lymphoma (HL), remains a significant challenge for resource-limited ones. This study aimed to describe the profile of HL in Togo. This was a retrospective, descriptive study conducted at the Clinical Hematology Department of the Campus University Hospital Center in Lomé, Togo. It focused on patient records diagnosed with HL between January 1, 2006, and December 31, 2022. Various variables such as age, gender, histological type of HL, Ann Arbor stage, prognostic classification, therapeutic protocol used, and patient outcomes were examined. The annual incidence of HL was 1.5 with a mean age of 38.7 years (range 12-63). Lymph node enlargement was the primary clinical sign (100%). Histologically, classical HL was found in 21 patients (87.5%). Staging was conducted for 16 (66.7%) patients, among whom 11 (66.7%) were at an advanced stage, and 6 (37.5%) had an unfavorable prognosis. The ABVD protocol was used in 13 patients (54.2%), receiving between 1 and 6 cycles. One patient achieved complete remission (4.1%), three deceased (12.5%), and 17 (71%) were lost to follow-up. Hodgkin's lymphoma prognosis remains unfavorable with low remission rates in Togo. Improving the technical facilities will ensure better management of this lymphoma.","PeriodicalId":517654,"journal":{"name":"Journal of Hematology and Oncology Research","volume":"57 3","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hodgkin's Lymphoma In Low-Income Countries: Experience Of Togo\",\"authors\":\"Essohana Padaro, K. M. C. Womey, Yao Layibo, Kadara R Adandodo, Hèzouwè Magnang, Mensah D I Kueviakoe\",\"doi\":\"10.14302/issn.2372-6601.jhor-24-4962\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"While highly curable in developed countries, Hodgkin's lymphoma (HL), remains a significant challenge for resource-limited ones. This study aimed to describe the profile of HL in Togo. This was a retrospective, descriptive study conducted at the Clinical Hematology Department of the Campus University Hospital Center in Lomé, Togo. It focused on patient records diagnosed with HL between January 1, 2006, and December 31, 2022. Various variables such as age, gender, histological type of HL, Ann Arbor stage, prognostic classification, therapeutic protocol used, and patient outcomes were examined. The annual incidence of HL was 1.5 with a mean age of 38.7 years (range 12-63). Lymph node enlargement was the primary clinical sign (100%). Histologically, classical HL was found in 21 patients (87.5%). Staging was conducted for 16 (66.7%) patients, among whom 11 (66.7%) were at an advanced stage, and 6 (37.5%) had an unfavorable prognosis. The ABVD protocol was used in 13 patients (54.2%), receiving between 1 and 6 cycles. One patient achieved complete remission (4.1%), three deceased (12.5%), and 17 (71%) were lost to follow-up. Hodgkin's lymphoma prognosis remains unfavorable with low remission rates in Togo. Improving the technical facilities will ensure better management of this lymphoma.\",\"PeriodicalId\":517654,\"journal\":{\"name\":\"Journal of Hematology and Oncology Research\",\"volume\":\"57 3\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hematology and Oncology Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14302/issn.2372-6601.jhor-24-4962\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hematology and Oncology Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14302/issn.2372-6601.jhor-24-4962","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在发达国家,霍奇金淋巴瘤(HL)的治愈率很高,但在资源有限的国家,它仍然是一项重大挑战。本研究旨在描述多哥霍奇金淋巴瘤的概况。这是一项回顾性、描述性研究,在多哥洛美校园大学医院中心的临床血液科进行。研究的重点是2006年1月1日至2022年12月31日期间确诊为HL的患者病历。对各种变量进行了研究,如年龄、性别、HL 的组织学类型、Ann Arbor 分期、预后分类、所用治疗方案和患者预后。HL的年发病率为1.5,平均年龄为38.7岁(12-63岁不等)。淋巴结肿大是主要的临床表现(100%)。组织学检查发现,21 名患者(87.5%)为典型的 HL。对16例(66.7%)患者进行了分期,其中11例(66.7%)处于晚期,6例(37.5%)预后不良。13名患者(54.2%)采用了ABVD方案,接受了1至6个周期的治疗。1名患者获得完全缓解(4.1%),3名患者死亡(12.5%),17名患者(71%)失去随访机会。在多哥,霍奇金淋巴瘤的预后仍然很差,缓解率很低。改善技术设施将确保更好地管理这种淋巴瘤。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Hodgkin's Lymphoma In Low-Income Countries: Experience Of Togo
While highly curable in developed countries, Hodgkin's lymphoma (HL), remains a significant challenge for resource-limited ones. This study aimed to describe the profile of HL in Togo. This was a retrospective, descriptive study conducted at the Clinical Hematology Department of the Campus University Hospital Center in Lomé, Togo. It focused on patient records diagnosed with HL between January 1, 2006, and December 31, 2022. Various variables such as age, gender, histological type of HL, Ann Arbor stage, prognostic classification, therapeutic protocol used, and patient outcomes were examined. The annual incidence of HL was 1.5 with a mean age of 38.7 years (range 12-63). Lymph node enlargement was the primary clinical sign (100%). Histologically, classical HL was found in 21 patients (87.5%). Staging was conducted for 16 (66.7%) patients, among whom 11 (66.7%) were at an advanced stage, and 6 (37.5%) had an unfavorable prognosis. The ABVD protocol was used in 13 patients (54.2%), receiving between 1 and 6 cycles. One patient achieved complete remission (4.1%), three deceased (12.5%), and 17 (71%) were lost to follow-up. Hodgkin's lymphoma prognosis remains unfavorable with low remission rates in Togo. Improving the technical facilities will ensure better management of this lymphoma.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信